Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats

Journal of Cardiovascular Pharmacology

Volumn 44, Issue SUPPL. 1, 2004, Pages

  Thöne Reinke, Christa ^a   Simon, Katja ^b   Richter, Claus Michael ^b   Godes, Michael ^b   Neumayer, Hans H ^b   Thormählen, Dirk ^c   Hocher, Berthold ^b,d  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c Solvay Pharmaceuticals GmbH   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Diabetic nephropathy; Endothelin converting enzyme (ECE); Neutral endopeptidase (NEP)

Indexed keywords

ALBUMIN; CAPTOPRIL; DAGLUTRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; MATRIX PROTEIN; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL MODEL; BLOOD PRESSURE; COMPUTER ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; KIDNEY FUNCTION; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN URINE LEVEL; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; URINARY EXCRETION;

ADMINISTRATION, ORAL; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ASPARTIC ENDOPEPTIDASES; BENZAZEPINES; BLOOD GLUCOSE; BLOOD PRESSURE; CAPTOPRIL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROSIS; KIDNEY; METALLOENDOPEPTIDASES; NEPRILYSIN; PROTEASE INHIBITORS; PROTEINURIA; RATS; RATS, WISTAR; TIME FACTORS;

EID: 11144267307     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000166208.12297.8d     Document Type: Conference Paper

References (17)

1. Ritz E. Nephropathy in type 2 diabetes. J Intern Med. 1999;245:111-126.
2. Shumway JT, Gambert SR. Diabetic nephropathy-pathophysiology and management. Int Urol Nephrol. 2002;34:257-264.
3. Svensson M, Sundkvist G, Amqvist HJ, et al. Signs of nephropathy may occur early in young adults with dial despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26:2903-2909.
4. Hocher B, Ziebig R, Altermann C, et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol. 2003;14:2329-2337.
5. Minchenko AG, Stevens MJ, White L, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J. 2003;17:1514-1156.
6. Hocher B, Lun A, Priem F, Neumayer HH, Raschack M. Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol. 1998.31:492-495.
7. Klahr S, Morrissey J. Progression of chronic renal disease. Am J Kidney Dis. 2003;41(Suppl. 1):S3-S7.
8. Hocher B, Thöne-Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop renal cysts, interstitial fibrosis and glomerulosclerosis but not hypertension. J Clin Invest. 1997;99:1380-1389.
9. Hocher B, Liefeldt L, Thöne-Reineke C, et al. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension. 1996;28:196-201.
10. Hocher B, Schwarz A, Reinbacher D, et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron. 2001;87:161-169.
11. Benigni A, Colosio V, Brena C, et al. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes. 1998;47:450-456.
12. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev. 1992;44:479-602.
13. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov. 2002;1:986-1001.
14. Tabrizchi R. SLV-306, Solvay. Curr Opin Investig Drugs. 2003;4:329-332.
15. Bader R, Bader H, Grund KE, et al. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters. Pathol Res Pract. 1980;167:204-216.
16. Mackensen S, Grund KE, Bader R, Bohle A. The influence of glomerular and interstitial factors on the serum creatinine concentration in renal amyloidosis. Virchows Arch A Pathol Anat Histol. 1977;375:159-168.
17. Müller DN, Mullally A, Dechend R, et al. Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension. 2002;40:840-846.